logo
Another hole has formed at Yellowstone National Park, geologists say

Another hole has formed at Yellowstone National Park, geologists say

Yahooa day ago
More geological changes are occurring at Yellowstone National Park, as another hole forms in one of the park's basins.
The hole is a blue water spring, discovered by geologists in April as they conducted routine maintenance of temperature logging stations at Norris Geyser Basin, according to the U.S. Geological Survey.
MORE: Hidden magma cap discovered at Yellowstone National Park
The pool, located in the Porcelain Basin sub-basin west of a patch of vegetation known as "Tree Island," was not there during their last visit to the area in the fall, according to the USGS.
The water is light blue in color and is about 1 foot deep below the rim. It's geological features indicate it formed as a result of a hydrothermal explosion -- an event caused by pressure changes that result from the transition of liquid water to steam, according to the USGS.
MORE: Researchers working to save whitebark pine, a declining keystone tree species in the greater Yellowstone area
The pool measures about 13 feet in diameter and is surrounded by numerous small rocks about 1 foot across. The rocks are covered by light gray, sandy mud.
It is "not surprising" that a hydrothermal explosion occurred at the site, as it has happened several times in recent decades, according to the USGS. The North Geyser Basin is the "most dynamic" area in Yellowstone, the agency said.
High-resolution satellite imagery indicates that the hole was not present on Dec. 19, but images taken on Jan. 6 show a depression that had formed in the area. By Feb. 13, the pool had been filled with water, the satellite images show.
More will hydrothermal explosions will likely be recorded, as a monitoring station installed in 2023 can detect geophysical data indicating an explosion.
MORE: Yellowstone visitors are getting so comfortable with approaching wildlife that park officials are asking them to stop
In April 2024, a "small" explosion at the Porcelain Terrace left a crater measuring several feet across in diameter, according to the USGS.
A hole that formed in Yellowstone's Biscuit Basin, near Old Faithful, in July 2024 was also attributed to a hydrothermal explosion, according to the National Park Service.
While that hole likely formed in a single major explosive event, the newest thermal feature appears to have formed by multiple small events that initially threw rocks but later threw silica mud a short distance, creating a small pit that became filled with silica-rich water.
MORE: Yellowstone supervolcano has a lot more magma than previously thought: Scientists
Geologists estimate that the feature probably started to develop on Dec. 25, with further activity occurring through late January and early February, according to the USGS.
Beneath Yellowstone National Park lies a complex and extensive volcanic system. The park is thoroughly monitored by the USGS and the Yellowstone Volcano Observatory.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Yahoo

time24 minutes ago

  • Yahoo

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ('Eledon') (Nasdaq: ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation will be presented at the World Transplant Congress (WTC) taking place in San Francisco from August 2-6, 2025. The oral presentation will feature updated results from approximately 30 kidney transplant recipients and will be presented by Dr. John Gill from the University of British Columbia. Details of the oral presentation are as follows: Title: Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b StudySession: Oral Presentation, Kidney Novel Immunosuppressant StrategiesPresenter: John Gill, MD, MS, University of British Columbia, Vancouver, CanadaSession Date and Time: Wednesday, August 6, 2025: 10:00 a.m. – 11:15 a.m. PT Following the session, a copy of the presentation can be found on the Investor section of the Company's website at The Company will also sponsor a satellite symposium at WTC titled: 'What Truly Defines Kidney Transplant Success: Early Rejection or Lasting Function?', to be held on Sunday, August 3, at 1:00 pm PT. Faculty include Allan Kirk, MD, Duke University School of Medicine, Oriol Bestard, MD, PhD, MD, Vall d'Hebron University Hospital, John Gill, MD, MS, University of British Columbia, Alexandre Loupy, MD, PhD, Necker Hospital and Deirdre Sawinski, MD, Weill Cornell Medical College. In addition to the oral presentation, new preclinical data, utilizing tegoprubart for the prevention of rejection in non-human primates undergoing liver transplantation, will be presented by Dr. Andrew Adams in a poster session: Title: Anti-CD154 Facilitates Long-Term Liver Allograft Survival in Non-Human PrimatesSession: Poster PresentationPresenter: Andrew Adams, MD, PhD, University of MinnesotaDate and Time: Sunday, August 3, 2025, 3:30 p.m. PT About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company's website at Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter Investor Contact: Stephen JasperGilmartin Group(858) 525 2047stephen@ Media Contact: Jenna UrbanCG Life(212) 253 8881jurban@ Source: Eledon Pharmaceuticals

Flesh-Eating Bacteria Have Already Killed Four People in Florida This Year
Flesh-Eating Bacteria Have Already Killed Four People in Florida This Year

Gizmodo

time25 minutes ago

  • Gizmodo

Flesh-Eating Bacteria Have Already Killed Four People in Florida This Year

A rare flesh-eating bacteria has killed four people in Florida this year, according to a recent report by the state's Department of Health. The deadly bacteria, Vibrio vulnificus, is typically found in warm saltwater or brackish water. It can enter the body through open cuts or by consuming raw shellfish, and the microbe is often found in oysters from warm coastal waters. Although infections are rare, the bacterium causes a disease called vibriosis, which is marked by gastrointestinal symptoms, fever, high heart rate, and disorientation. In some cases, it can lead to necrotizing fasciitis, a condition in which bacteria rapidly destroy muscle and tissue. According to the CDC, many people with Vibrio vulnificus infections require intensive care or even limb amputation. Roughly one in five people who contract a Vibrio vulnificus infection die, and people with weakened immune systems are particularly at risk. Florida has reported 11 cases this year. Around 150 to 200 cases of Vibrio vulnificus are reported to the CDC each year in the U.S., although experts believe the actual number may be higher. Cases have been on the rise in recent years. In 2022 and 2024, deaths and infections spiked after Hurricanes Helene and Milton, which washed saltwater inland. The department reported a record 19 deaths and 82 cases last year, an increase of seven deaths and nearly double the number of cases in 2023. For Vibrio vulnificus, another bacteria in the Vibrio family (who are generally less deadly), temperature and salinity are key growth factors, conditions that are becoming more common due to climate change, according to a report in Scientific American. Rising global temperatures also mean that hurricanes will become more frequent and stronger. A report by the U.S. Department of Agriculture stated that climate change will increase the cost of Vibrio infections from $2.6 billion in 1995 to between $6.1 and $8.6 billion by 2090. Worryingly, the microbes are extremely adaptable and can frequently acquire new traits. A 2023 study found that Vibrio pathogens are adapting to 'stick' to microplastics, for example. Florida Health officials caution against entering warm saltwater or brackish water if any fresh cuts, scrapes, or wounds are present. Consuming raw shellfish is also not recommended, unfortunately.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store